CHF 40,000 for a solution for the treatment of mitral regurgitation, a software for epilepsy diagnosis, and an innovative shopping platform
25.11.2024
Adjust Medical, dEEGtal, and JOSEPHA were selected at Venture Kick's second financial and entrepreneurial support stage. Their projects develop a minimalist simple solution for the treatment of mitral regurgitation; develop a software to assist neurologists in the diagnosis of epilepsy: and aggregate all product-related information and make it interactively accessible, saving consumers valuable time with every purchase.
 |
 |
 Adjust Medical: Co-Founders Youssef Biadillah, Vitali Verin, Giovanni Leo, and Aristotelis Panos
|
|
 JOSEPHA: CEO Silvan Weder and CPO Josef Gitterle
|
|
 dEEGtal: CTO Stefano Gallotto, Advisor and Co-Founder Margitta Seeck, and CEO Eric Ménétré
|
|
Adjust Medical: Minimalist Simple Solution for the treatment of Mitral Regurgitation
Primary mitral regurgitation (MR) is the most common heart valve pathology affecting 2% of the general population and is associated with decreased mid- and long-term survival rates. In the US alone, 2 million patients suffer from MR and that number is expected to double by 2030. Few minimally invasive, catheter-based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and the inability to treat patients with other devices subsequently.
Adjust Medical has developed the AdjusTer™: A small, form-factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options. The company was founded by Dr. Vitali Verin, an interventional cardiologist at Clinique de Genolier, Vaud, Dr
Aristotelis Panos, mitral valve surgeon at Hôpital de La Tour, Geneva, Mr. Giovanni Leo, a medical device executive with 30 years of experience, and Mr. Youssef Biadillah, a medical device executive with 20 years of experience.
The Venture Kick funds will help the company move from in-vitro to in-vivo pre-clinical testing.
dEEGtal: Empowering Epilepsy Diagnosis
The diagnosis of epilepsy is mostly based on visual interpretation of the electroencephalogram (EEG). This method inherently does not provide a diagnosis in 75-80% of the cases, making the diagnosis challenging, in turn affecting patients' quality of life and worsening their prognosis.
dEEGtal stems from Dr. Eric Ménétré and Dr. Stefano Gallotto who, by bringing together expertise in clinical research, neuroscience, and AI, are developing a software to assist neurologists in the diagnosis of epilepsy. The software extracts information from the EEG that is not available with current EEG reading methods and provides an AI-calculated risk score of epilepsy. In a growing global epilepsy diagnostics market valued at $3.3 billion, dEEGtal is part of an environment that provides a substantial opportunity for growth.
Securing the first stage of Venture Kick funding will enable dEEGtal to conduct thorough market research and validate their market entry, regulatory, and IP strategies. This will set the stage for successful market entry.
JOSEPHA: a centralized shopping platform with all product information
Relevant information about products is scattered across the internet. Consumers waste hours jumping between websites to compare prices, read reviews, watch tutorial videos, and gather product information to find the best product for them. Current search engines and comparison platforms fail to bring everything together in one place, leaving users frustrated by fragmented data and time-consuming searches.
JOSEPHA was founded by Dr. Silvan Weder and Josef Gitterle, who bring together years of experience in AI and commerce. Their shopping platform aggregates all product-related information and makes it interactively accessible, saving consumers valuable time with every purchase. Josepha is a shopping platform that centralizes all product information (reviews, offers, tutorial videos, and more) and makes this product information interactively accessible to consumers. The e-commerce market is vast, with over 27 billion monthly product searches. JOSEPHA disrupts this space by providing the platform where all your shopping happens.
JOSEPHA will use the Venture Kick funds to develop its product discovery feature further and enhance user acquisition through organic social media strategies. These efforts will accelerate its growth in the DACH region.
Primary mitral regurgitation (MR) is the most common heart valve pathology affecting 2% of the general population and is associated with decreased mid- and long-term survival rates. In the US alone, 2 million patients suffer from MR and that number is expected to double by 2030. Few minimally invasive, catheter-based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and the inability to treat patients with other devices subsequently.
Adjust Medical has developed the AdjusTer™: A small, form-factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options. The company was founded by Dr. Vitali Verin, an interventional cardiologist at Clinique de Genolier, Vaud, Dr
Aristotelis Panos, mitral valve surgeon at Hôpital de La Tour, Geneva, Mr. Giovanni Leo, a medical device executive with 30 years of experience, and Mr. Youssef Biadillah, a medical device executive with 20 years of experience.
The Venture Kick funds will help the company move from in-vitro to in-vivo pre-clinical testing.
dEEGtal: Empowering Epilepsy Diagnosis
The diagnosis of epilepsy is mostly based on visual interpretation of the electroencephalogram (EEG). This method inherently does not provide a diagnosis in 75-80% of the cases, making the diagnosis challenging, in turn affecting patients' quality of life and worsening their prognosis.
dEEGtal stems from Dr. Eric Ménétré and Dr. Stefano Gallotto who, by bringing together expertise in clinical research, neuroscience, and AI, are developing a software to assist neurologists in the diagnosis of epilepsy. The software extracts information from the EEG that is not available with current EEG reading methods and provides an AI-calculated risk score of epilepsy. In a growing global epilepsy diagnostics market valued at $3.3 billion, dEEGtal is part of an environment that provides a substantial opportunity for growth.
Securing the first stage of Venture Kick funding will enable dEEGtal to conduct thorough market research and validate their market entry, regulatory, and IP strategies. This will set the stage for successful market entry.
JOSEPHA: a centralized shopping platform with all product information
Relevant information about products is scattered across the internet. Consumers waste hours jumping between websites to compare prices, read reviews, watch tutorial videos, and gather product information to find the best product for them. Current search engines and comparison platforms fail to bring everything together in one place, leaving users frustrated by fragmented data and time-consuming searches.
JOSEPHA was founded by Dr. Silvan Weder and Josef Gitterle, who bring together years of experience in AI and commerce. Their shopping platform aggregates all product-related information and makes it interactively accessible, saving consumers valuable time with every purchase. Josepha is a shopping platform that centralizes all product information (reviews, offers, tutorial videos, and more) and makes this product information interactively accessible to consumers. The e-commerce market is vast, with over 27 billion monthly product searches. JOSEPHA disrupts this space by providing the platform where all your shopping happens.
JOSEPHA will use the Venture Kick funds to develop its product discovery feature further and enhance user acquisition through organic social media strategies. These efforts will accelerate its growth in the DACH region.